Cargando…

Dual-responsive doxorubicin-loaded nanomicelles for enhanced cancer therapy

BACKGROUND: The enhancement of tumor retention and cellular uptake of drugs are important factors in maximizing anticancer therapy and minimizing side effects of encapsulated drugs. Herein, a delivery nanoplatform, armed with a pH-triggered charge-reversal capability and self-amplifiable reactive ox...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xinyi, Zhu, Tiantian, Miao, Yaxin, Zhou, Lu, Zhang, Weifang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7517807/
https://www.ncbi.nlm.nih.gov/pubmed/32972412
http://dx.doi.org/10.1186/s12951-020-00691-6
_version_ 1783587298547335168
author Zhang, Xinyi
Zhu, Tiantian
Miao, Yaxin
Zhou, Lu
Zhang, Weifang
author_facet Zhang, Xinyi
Zhu, Tiantian
Miao, Yaxin
Zhou, Lu
Zhang, Weifang
author_sort Zhang, Xinyi
collection PubMed
description BACKGROUND: The enhancement of tumor retention and cellular uptake of drugs are important factors in maximizing anticancer therapy and minimizing side effects of encapsulated drugs. Herein, a delivery nanoplatform, armed with a pH-triggered charge-reversal capability and self-amplifiable reactive oxygen species (ROS)-induced drug release, is constructed by encapsulating doxorubicin (DOX) in pH/ROS-responsive polymeric micelle. RESULTS: The surface charge of this system was converted from negative to positive from pH 7.4 to pH 6.8, which facilitated the cellular uptake. In addition, methionine-based system was dissociated in a ROS-rich and acidic intracellular environment, resulting in the release of DOX and α-tocopheryl succinate (TOS). Then, the exposed TOS segments further induced the generation of ROS, leading to self-amplifiable disassembly of the micelles and drug release. CONCLUSIONS: We confirms efficient DOX delivery into cancer cells, upregulation of tumoral ROS level and induction of the apoptotic capability in vitro. The system exhibits outstanding tumor inhibition capability in vivo, indicating that dual stimuli nano-system has great potential to function as an anticancer drug delivery platform. [Image: see text]
format Online
Article
Text
id pubmed-7517807
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-75178072020-09-29 Dual-responsive doxorubicin-loaded nanomicelles for enhanced cancer therapy Zhang, Xinyi Zhu, Tiantian Miao, Yaxin Zhou, Lu Zhang, Weifang J Nanobiotechnology Research BACKGROUND: The enhancement of tumor retention and cellular uptake of drugs are important factors in maximizing anticancer therapy and minimizing side effects of encapsulated drugs. Herein, a delivery nanoplatform, armed with a pH-triggered charge-reversal capability and self-amplifiable reactive oxygen species (ROS)-induced drug release, is constructed by encapsulating doxorubicin (DOX) in pH/ROS-responsive polymeric micelle. RESULTS: The surface charge of this system was converted from negative to positive from pH 7.4 to pH 6.8, which facilitated the cellular uptake. In addition, methionine-based system was dissociated in a ROS-rich and acidic intracellular environment, resulting in the release of DOX and α-tocopheryl succinate (TOS). Then, the exposed TOS segments further induced the generation of ROS, leading to self-amplifiable disassembly of the micelles and drug release. CONCLUSIONS: We confirms efficient DOX delivery into cancer cells, upregulation of tumoral ROS level and induction of the apoptotic capability in vitro. The system exhibits outstanding tumor inhibition capability in vivo, indicating that dual stimuli nano-system has great potential to function as an anticancer drug delivery platform. [Image: see text] BioMed Central 2020-09-24 /pmc/articles/PMC7517807/ /pubmed/32972412 http://dx.doi.org/10.1186/s12951-020-00691-6 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Zhang, Xinyi
Zhu, Tiantian
Miao, Yaxin
Zhou, Lu
Zhang, Weifang
Dual-responsive doxorubicin-loaded nanomicelles for enhanced cancer therapy
title Dual-responsive doxorubicin-loaded nanomicelles for enhanced cancer therapy
title_full Dual-responsive doxorubicin-loaded nanomicelles for enhanced cancer therapy
title_fullStr Dual-responsive doxorubicin-loaded nanomicelles for enhanced cancer therapy
title_full_unstemmed Dual-responsive doxorubicin-loaded nanomicelles for enhanced cancer therapy
title_short Dual-responsive doxorubicin-loaded nanomicelles for enhanced cancer therapy
title_sort dual-responsive doxorubicin-loaded nanomicelles for enhanced cancer therapy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7517807/
https://www.ncbi.nlm.nih.gov/pubmed/32972412
http://dx.doi.org/10.1186/s12951-020-00691-6
work_keys_str_mv AT zhangxinyi dualresponsivedoxorubicinloadednanomicellesforenhancedcancertherapy
AT zhutiantian dualresponsivedoxorubicinloadednanomicellesforenhancedcancertherapy
AT miaoyaxin dualresponsivedoxorubicinloadednanomicellesforenhancedcancertherapy
AT zhoulu dualresponsivedoxorubicinloadednanomicellesforenhancedcancertherapy
AT zhangweifang dualresponsivedoxorubicinloadednanomicellesforenhancedcancertherapy